Treatment of Herpes Labialis (Cold Sores)
For immunocompetent adults with herpes labialis, initiate short-course oral antiviral therapy with either valacyclovir 2g twice daily for 1 day or famciclovir 1500mg as a single dose at the first sign of symptoms (prodrome or within 24 hours of lesion onset) to accelerate healing and reduce pain duration. 1
Episodic Treatment Approach
First-Line Oral Antivirals (Preferred)
Oral antivirals are superior to topical agents and should be the primary treatment choice 2, 3:
Valacyclovir: 2g twice daily for 1 day (FDA-approved regimen) 1
Acyclovir: 400mg five times daily for 5 days (alternative if above unavailable) 1, 3
Timing is Critical
Treatment must be initiated within the first 24-48 hours of symptom onset, ideally during the prodrome (tingling, burning, itching), to achieve optimal therapeutic benefit 1, 2. Peak viral titers occur in the first 24 hours when lesions are vesicular, making early intervention essential 1.
Topical Antivirals (Second-Line)
Use only when oral therapy is contraindicated or unavailable 1:
Penciclovir 1% cream: Apply every 2 hours while awake for 4 days 5
- Reduces healing time by 0.7 days (median 4.8 vs 5.5 days with placebo) 5
Acyclovir 5% cream: Apply 5 times daily for 4-5 days 3
- Provides small clinical benefit 1
Docosanol 10% cream: Available over-the-counter 6
- Safe but essentially equivalent efficacy to other topical agents 6
Important caveat: Topical antivirals provide only modest benefit (reducing duration by less than 1 day) and require frequent application, making them less convenient than oral therapy 1. They are not effective for prophylaxis 1.
Chronic Suppressive Therapy
For patients with severe or frequent recurrences (≥6 episodes per year), initiate daily suppressive oral antiviral therapy 2:
Valacyclovir: 500mg once daily 1
Acyclovir: 400mg twice daily 1
- Reduces frequency of attacks and symptom duration 1
Famciclovir: 250mg twice daily (alternative) 1
Suppressive therapy has been shown to reduce clinical recurrences by 53% compared to placebo 1.
Prophylaxis for Trigger-Related Recurrences
For patients with UV light-triggered recurrences, use sunscreen (SPF ≥15) or zinc oxide 1, 3. This is a simple, non-pharmacologic intervention that can reduce outbreak frequency 1.
Safety Profile
All three oral antivirals (acyclovir, valacyclovir, famciclovir) are well-tolerated with minimal adverse events 1:
- Most common side effects: headache (<10%), nausea (<4%) 1
- Adverse events are mild-to-moderate and similar to placebo rates 1
- No serious adverse events reported in clinical trials 1
Common Pitfalls to Avoid
Delayed treatment initiation: Waiting beyond 48 hours significantly reduces efficacy 2. Patients should be educated to self-initiate therapy at first symptoms 1.
Using topical antivirals for prevention: Topical agents do not reach the site of viral reactivation in sensory ganglia and are ineffective prophylactically 1.
Inadequate treatment of frequent recurrences: Patients with ≥6 episodes per year benefit more from daily suppressive therapy than episodic treatment 2.
Confusing with primary gingivostomatitis: While oral acyclovir reduces healing time for primary HSV-1 gingivostomatitis, no antiviral is FDA-approved for this indication 1.
Special Considerations
Immunocompromised patients: Episodes are longer and more severe, potentially involving the oral cavity or extending across the face 1. These patients require longer treatment courses and may benefit from chronic suppression 1.
Self-limiting disease: Many patients do not require treatment as herpes labialis is self-limiting 1. Treatment is warranted when patients desire relief from pain, cosmetic concerns, or social stigma 1.
Resistance risk: Minimal with appropriate use of oral antivirals 1. Docosanol has essentially no resistance risk due to its unique mechanism of action 6.